Health breakthroughs and money matters, in plain words

Home » Three Antidepressants Outperform Fluoxetine in Major Long-Term Effectiveness Study

Three Antidepressants Outperform Fluoxetine in Major Long-Term Effectiveness Study

By

–

Three Antidepressants Outperform Fluoxetine in Major Long-Term Effectiveness Study

A major study published in The Lancet Psychiatry has found that three antidepressants — escitalopram, duloxetine, and agomelatine — provided more enduring relief from depression symptoms than fluoxetine, the widely known medication often sold under the brand name Prozac. Researchers analyzed 115 clinical trials involving more than 30,000 people to compare how well 20 different antidepressants worked over the long term.

What the Study Found

The meta-analysis, led by researchers at Radboud University Medical Center in the Netherlands, looked at whether patients experienced a “sustained response” — meaning their symptoms improved and stayed improved until the trial ended. Trials included in the analysis lasted from 12 weeks to two years, far longer than the typical eight-week clinical trial. Fluoxetine was used as the main comparison drug because it is widely prescribed and well studied.

Patients taking escitalopram (sold as Lexapro), duloxetine (Cymbalta), or agomelatine were more likely to see their symptoms improve and remain better compared to those taking fluoxetine. The study also found that bupropion (Wellbutrin) and reboxetine (Edronax) performed worse than multiple other antidepressants in the analysis. Among the selective serotonin reuptake inhibitors, or SSRIs, escitalopram appeared to work best at helping patients stay well over time.

Context: Why Long-Term Data Matters

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction. While they are commonly prescribed — with as many as 20% of U.S. adults reporting experiences with depression — most clinical trials last only about eight weeks. That leaves a gap in evidence for patients and doctors making decisions about treatment that often continues for years.

The new analysis helps fill that gap by tracking outcomes over months and years. It also examined whether patients stopped taking their medication for any reason, assuming that discontinuation often signaled the treatment was not working or was not tolerated.

Side Effects and Safety Considerations

Common side effects of antidepressants include dry mouth, weight gain, dizziness, headaches, sexual dysfunction, and emotional blunting. The medications also carry an increased risk of suicidal thinking and behavior in children, adolescents, and young adults.

Paul van Haaren, a researcher at Radboud University Medical Center who worked on the study, noted that the three top-performing drugs have different benefits and drawbacks. Escitalopram is already widely used as a first-line option. Agomelatine works well but carries a risk of liver failure. Duloxetine is prescribed less frequently as a first-line treatment. Eric Ruhé, a professor of difficult-to-treat depression at Radboud, said the findings could eventually influence prescribing, but stressed that the balance between benefits and side effects differs from person to person.

Availability and Limitations

Dr. Carole Lieberman, a board-certified psychiatrist in Beverly Hills who was not involved in the study, urged caution. She noted that agomelatine is not approved in the United States. Eli Lilly, the original manufacturer of Prozac, stated it discontinued manufacturing the brand-name drug in 2024, though fluoxetine remains available in many FDA-approved generic versions.

The researchers emphasized that the findings do not mean everyone with depression should switch to escitalopram or the other top performers. Treatment decisions depend on individual medical history, side effect profiles, and how a patient responds. Patients should talk to their doctor before making any changes to their medication.

Sources

Photo: Radboud University Nijmegen Medical Centre (UMC St Radboud) (CC BY-SA 3.0)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News